However, when they received anti-PD1/anti-PD-L1 plus chemotherapy, women statistically benefited more than men, suggesting that the utilization of anti-neoplasm drugs can enhance the efficacy of immunotherapy in women, potentially becoming a future application scenario for PCSK9is. This evidence concerns the gene PDCD1 and neoplasm.